Johnson & Johnson Faces $400M in Tariff Costs/ Newslooks/ WASHINGTON/ J. Mansour/ Morning Edition/ Johnson & Johnson expects $400 million in tariff-related expenses in 2025, primarily due to U.S.-China trade tensions. Most of the impact will hit the company’s medical technology division, with additional costs from steel, aluminum, and tariffs on Canada and Mexico. The company is pushing for tax-based incentives over tariffs as it plans to invest $55 billion in U.S.-based pharmaceutical production.
Johnson & Johnson Faces $400 Million Tariff Impact – Quick Looks
- Tariff Hit: J&J expects $400 million in costs from tariffs in 2025.
- China Focus: Most expenses stem from U.S.-China and retaliatory Chinese tariffs.
- Medical Tech Affected: The company’s medical technology unit will be hardest hit.
- Steel & Aluminum Tariffs: Additional impact from duties on raw materials like steel and aluminum.
- Price Flexibility Limited: Existing contracts restrict J&J from raising prices in response.
- Pharma Tariffs Loom: J&J warned of supply chain risks if pharmaceutical tariffs are enacted.
- U.S. Manufacturing Push: Company will invest $55B to localize advanced medicine production.
- Policy Preference: CEO advocates tax incentives over tariffs to boost domestic production.
Johnson & Johnson Faces $400M in Tariff Costs
Deep Look
Johnson & Johnson, one of the world’s leading healthcare and pharmaceutical companies, is bracing for a $400 million financial hit this year due to rising tariff-related costs—mainly from its operations involving China, executives said Tuesday.
Chief Financial Officer Joseph Wolk revealed the projection during a conference call with analysts following the release of the company’s latest quarterly earnings report. The burden, he noted, would fall largely on the company’s medical technology division, which produces surgical tools, orthopedic implants, and diagnostic equipment sold globally.
Wolk cited tariffs imposed on Chinese imports and retaliatory Chinese tariffs as the most significant contributors to the projected $400 million in added costs. Other contributing factors include tariffs on raw materials like aluminum and steel, as well as additional duties related to Canada and Mexico, key U.S. trade partners.
Contract Limits and Price Pressures
One of the key challenges for J&J in mitigating the impact of these tariffs is the presence of long-standing contractual agreements, which limit the company’s ability to pass on the extra costs to customers through price hikes.
“This makes absorbing the costs more difficult,” Wolk explained. “We are working hard to manage the margins, but we are restrained by our pricing structures, especially in hospital supply chains.”
Pharma Tariff Concerns
Importantly, the $400 million projection does not yet account for possible pharmaceutical tariffs, which are currently under investigation by the Trump administration as part of a broader push to reduce foreign reliance in the healthcare supply chain.
CEO Joaquin Duato warned that such tariffs—if enacted—could lead to supply chain disruptions, shortages of essential medications, and increased pressure on healthcare providers.
“We strongly believe the best way to incentivize domestic manufacturing isn’t through punitive tariffs, but through smart tax policy and investment incentives,” Duato said.
Massive U.S. Manufacturing Investment Planned
To bolster domestic production and reduce reliance on foreign pharmaceutical ingredients, Johnson & Johnson announced a $55 billion investment over the next four years to expand advanced medicine manufacturing facilities in the United States.
Duato said the initiative is part of a long-term plan to ensure that all medicines distributed in the U.S. are made in the U.S., a strategy aimed at both economic resilience and national security.
You must Register or Login to post a comment.